Get the Full Scoop: Why TC BioPharm (NASDAQ: TCBP) Is in Focus Early This Morning

*Sponsored Market Crux Announces TC BioPharm (NASDAQ: TCBP) As Our Next Potential Breakout Idea! After Friday’s Profile Moved Approximately 155% Before the  Opening Bell – Our Focus is Now On (TCBP). And Here’s Why… TC BioPharm (NASDAQ: TCBP) recently announced a special dividend, offering 0.25 ADSs for every 1 ADS held, showcasing its commitment to those who support it. With fewer than 585K shares outstanding, TC BioPharm (NASDAQ: TCBP) has a low float, increasing its susceptibility to significant fluctuations. HC Wainwright & Co. has set a $3 target for TC BioPharm (NASDAQ: TCBP), suggesting over 300% upside potential from Friday’s open. Consider Adding TC BioPharm (NASDAQ: TCBP) To Your  Radar This Week… December 30, 2024 Dear Reader, After the streak we've been on, with several profiles showing significant moves recently, it’s time to look ahead to our next potential breakout: 12/26: Approximate 155% move overnight. 12/23: Approximate 27% move in 1 day. 12/18: Approximate 30% move in 1 day. 12/11 to 12/12: Approximate 18% move overnight. 12/10 to 12/11: Approximate 25% move in 20 minutes after the opening bell. 12/10: Approximate 130% move after hours. 12/4 to 12/13: Approximate 79% move in just over a week. With that momentum, we are now turning our focus to one of our favorite sectors. The disease treatment sector is one of the few industries where small companies can see rapid growth practically overnight. When a major breakthrough occurs, it captures the attention of the market. One such breakthrough is gamma-delta T-cell therapy, offering a combination of precision and effectiveness that could redefine how serious diseases are treated. It’s not just a step forward; it’s a new way of thinking about treatment. At the forefront of this transformation is TC BioPharm (NASDAQ: TCBP).  By harnessing the unique abilities of gamma-delta T cells to distinguish between healthy and diseased tissues, they’re setting a new standard in modern medicine and targeting conditions like acute myeloid leukemia with unmatched precision. This is what happens when bold science meets fearless execution.  In fact, a few weeks ago, on December 6th, Benzinga reported that one of the country's oldest and most trusted institutions, HC Wainwright & Co., issued a $3 target on TC BioPharm (NASDAQ: TCBP). This suggests a potential upside of over 316% from Friday’s opening of around $.72. And with MarketWatch suggesting fewer than 585K shares outstanding, TC BioPharm (NASDAQ: TCBP)’s limited supply could lead to the potential for significant swings.  Keep reading to see why TC BioPharm (NASDAQ: TCBP) is #1 on our watchlist for Monday morning… The Power of Gamma-Delta T-Cells Gamma-delta T cells are unlike any other players in the immune system.  They combine the best of two worlds: the innate immune system's instinctive defense mechanisms and the adaptive immune system's precision targeting.  These cells can identify and destroy diseased tissues while leaving healthy cells untouched—an elusive goal in cancer treatment. TC BioPharm (NASDAQ: TCBP) has turned this natural advantage into a therapeutic powerhouse with TCB008. In preclinical studies, TCB008 has demonstrated a remarkable ability to eliminate acute myeloid leukemia (AML) cells in just 24 hours.  Even more impressive, it achieved this without harming healthy tissue, proving it’s as safe as it is effective. ACHIEVE Trials: Raising the Bar The ACHIEVE clinical trials are more than a test of TCB008—they are a challenge to conventional cancer treatment.  These Phase 2B trials focus on refractory and relapsed AML patients, a population with few options and fewer success stories. The results speak volumes. Early data from the safety cohort revealed no dr-ug-related adverse events and stable disease in 40% of patients.  These outcomes are not just encouraging; they are a clear indication that TCB008 is charting a new path for AML therapy. With top-tier clinical sites like King’s College Hospital and Guy’s and St. Thomas Hospital leading the way, the ACHIEVE trials are laying the groundwork for a global impact.  Data from Cohort A, expected in late 2025, will be pivotal, while plans for the ACHIEVE2 (US) trial in 2026 promise to expand the reach of this breakthrough therapy. Beyond AML: A Broader Mission TC BioPharm (NASDAQ: TCBP)’s ambitions extend far beyond AML.  The company’s robust pipeline includes innovative therapies targeting solid tumors, viral infections, and other challenging conditions.  With expertise in CAR-T and CAR-NK technologies complementing its gamma-delta T-cell platform, TC BioPharm (NASDAQ: TCBP) is uniquely positioned to address a wide range of medical needs. TCB008’s versatility is a key strength. Preclinical studies have shown its effectiveness against glioblastoma and its safety across various healthy tissues, underscoring its potential as a foundation for next-generation combination therapies.  Strategic Acquisitions: Accelerating Growth and Innovation In the fast-moving biotech sector, acquisitions are a key driver of growth. Major players like AstraZeneca, Merck, and Johnson & Johnson are acquiring innovative startups and clinical-stage companies to enhance their portfolios and expedite the development of breakthrough treatments. TC BioPharm (NASDAQ: TCBP) is actively exploring strategic acquisitions to expand its pipeline and strengthen its leadership in the cell therapy space. By acquiring complementary technologies, TC BioPharm aims to accelerate its mission to revolutionize cancer treatment. Here are some notable acquisitions in 2024: AstraZeneca – Fusion Pharmaceuticals, $2.4B; Amolyt Pharma, $1.05B AbbVie – Landos Biopharma, $200M; Celsius Therapeutics, $250M Johnson & Johnson – V-Wave, $600M; Shockwave Medical, $13.1B Merck – Curon, $750M; Modifi Biosciences, $1.6B Novartis – Kate Therapeutics, $425M; Mariana Oncology, $1B Sanofi – Inhibrx, $2.2B These acquisitions highlight the growing trend in biotech, and TC BioPharm is well-positioned to follow suit, ensuring it remains at the forefront of innovation in cell therapy. Partnerships That Drive Innovation Behind every great breakthrough are strong collaborations, and TC BioPharm (NASDAQ: TCBP) has forged alliances with some of the best in the business.  Its partnership with Carnegie Mellon University is harnessing artificial intelligence to enhance donor screening, making therapy development faster and more precise. In collaboration with Queen Mary University of London, TC BioPharm (NASDAQ: TCBP) is exploring the therapeutic potential of gamma-delta T cells for treating mucosal infections.  These efforts highlight the company’s commitment to expanding the boundaries of cell therapy. Fully Integrated Excellence TC BioPharm (NASDAQ: TCBP) follows a vertically integrated approach, from R&D to product manufacturing, ensuring control and efficiency at every stage. This strategy enables the company to rapidly advance its therapies while maintaining the highest quality standards. By managing every step of the process in-house, TC BioPharm (NASDAQ: TCBP) drives innovation and keeps the focus on delivering cutting-edge solutions. A New Era in Oncology TC BioPharm (NASDAQ: TCBP) is more than just a biotech company—it’s a movement toward a new era of cancer treatment.  Its pioneering gamma-delta T-cell therapies are not only offering hope to patients with few options but also redefining what is possible in oncology.  With a bold vision, cutting-edge science, and an unwavering commitment to progress, TC BioPharm is leading the charge into a future where cancer meets its match. This isn’t just progress—it’s transformation. The future of medicine is here, and TC BioPharm (NASDAQ: TCBP) is making it happen. Recent Developments TC BioPharm (NASDAQ: TCBP) Reports Key Milestone in ACHIEVE Phase 2b Trial for TCB008 TC BioPharm has made significant strides in its ACHIEVE Phase 2b trial for TCB008, a treatment for AML and MDS/AML. The trial has shown no dru-g-related adverse events, with 3 patients completing the full-dose regimen. Recruitment has been rapid, and preliminary safety data indicates the treatment is well tolerated.  The company is on track to complete Cohort B enrollment by 2025.  TC BioPharm (NASDAQ: TCBP) Announces Special Dividend The Board of Directors at TC BioPharm has approved a special dividend of 0.25 ADSs for every 1 ADS held, pending shareholder approval. If approved at the general meeting on December 30, 2024, the dividend will be paid to shareholders by January 2, 2025.  CEO Bryan Kobel highlighted the company’s commitment to rewarding shareholders for their continued loyalty despite recent challenges.  TC BioPharm (NASDAQ: TCBP) and CareDx Team Up for Advanced Monitoring in AML Cell Therapy Trial TC BioPharm has partnered with CareDx to enhance its ACHIEVE clinical trial for TCB008. CareDx will use its AlloCell™ solution for pharmacokinetic analysis, helping monitor the expansion and persistence of TCB008 in AML patients.  This collaboration is key to optimizing TCB008 for AML and other blood cancers.  Consider Adding TC BioPharm (NASDAQ: TCBP) To Your Radar This Week… TC BioPharm (NASDAQ: TCBP) is a company to watch closely. With an ambitious $3 target set by HC Wainwright & Co., suggesting a 316% upside potential from Friday’s open, (TCBP) is poised for significant growth. The company has less than 585K shares outstanding, as reported by MarketWatch, which further amplifies its potential for substantial fluctuations, for those looking for volatility. Adding to the appeal, TC BioPharm (NASDAQ: TCBP)’s recent special dividend demonstrates its commitment to rewarding loyal shareholders, further solidifying its investor-friendly approach. The company’s ACHIEVE Phase 2b trial is advancing smoothly, with no adverse dr-ug-related events reported and rapid patient enrollment, signaling growing demand for its groundbreaking gamma-delta T-cell therapy. With strategic collaborations like its partnership with CareDx, enhancing data precision through AlloCell™ monitoring, TC BioPharm (NASDAQ: TCBP) is positioning itself as a leader in the fight against AML, MDS, and other cancers. Coupled with its expanding pipeline targeting solid tumors, viral infections, and more, the company’s future looks bright with sustained growth on the horizon. TC BioPharm (NASDAQ: TCBP) is not just advancing science — it’s rewriting the future of oncology and beyond. The road ahead is filled with potential, which is why we’re keeping an eye on this innovative leader in cell therapy. 5 Reasons Why TC BioPharm (NASDAQ: TCBP) Is #1 On Our Watchlist This Morning… 1. Low Float: With fewer than 585K shares outstanding according to MarketWatch, TC BioPharm (NASDAQ: TCBP) has a low float, making it especially susceptible to significant fluctuations.  2. Analyst Target: HC Wainwright & Co. has issued a $3 target for TC BioPharm (NASDAQ: TCBP), suggesting a 316% upside potential from Friday’s open.  3. Special Dividend: Recently, TC BioPharm (NASDAQ: TCBP) announced a special dividend, rewarding shareholders with 0.25 ADSs for every 1 ADS held. This shareholder-friendly move highlights the company’s dedication to those who have supported it through its growth. 4. Innovative Gamma-Delta T-Cell Therapy: TC BioPharm (NASDAQ: TCBP)’s gamma-delta T-cell therapy is revolutionizing AML and MDS treatment by targeting diseased cells without harming healthy tissue. This breakthrough approach could transform oncology, positioning TC BioPharm as a leader in next-generation cancer therapies. 5. Expanding Pipeline: TC BioPharm (NASDAQ: TCBP) is advancing therapies for solid tumors, viral infections, and other critical conditions. With a growing and diversified pipeline, the company is positioning itself for sustained growth across multiple high-demand medical fields. TC BioPharm (NASDAQ: TCBP) has a low float of fewer than 585K shares outstanding according to MarketWatch, making it ripe for big swings. HC Wainwright’s $3 target suggests a 316% potential upside, adding to the excitement.   Get ready because we’ll be watching (TCBP) very closely this morning. We have (TCBP) at the top of our watchlist right now. My next update could be here any minute so keep a lookout for it. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 12/29/2024 and ending on 12/30/2024 to publicly disseminate information about (TCBP:US) via digital communications. Under this agreement, Headline Media LLC has been paid six thousand USD (“Funds”) to disseminate information about (TCBP:US) via digital communications. These Funds were part of the funds that TD Media, LLC received from a third party who does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their members own shares of (TCBP:US). Please see important disclosure information here: https://marketcrux.com/disclosure/tcbp/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice